This is analogous to how 5-Amino-1MQ works in metabolic research-rather than adding a new signal, it removes a brake on an existing one (NNMT inhibition preserves NAD+
Considering Formulation Complexity and Regulatory Factors
Some trainers and owners are interested in nasal delivery because it may offer: Ease of administration Potentially fast absorption through nasal tissues Avoidance of injection-site irritation But again, equine use of peptide nasal sprays is experimental, and product quality varies widely between suppliers
Ayton, S., Lei, P
Citations Citations to this article as recorded by Comments on Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficultto- treat inflammatory bowel disease: a single-center retrospective study in Japan Chenchen Xu, Hailing Li Intestinal Research.2026;[Epub] CrossRef Real-world effectiveness and predictors of need for extended induction of mirikizumab therapy in ulcerative colitis Cathy McShane, Itay Kalisky, Jonah S Moore, Raquel Milgrom, Joanne Stempak, Pablo A Olivera, Geoffrey Nguyen, Kenneth Croitoru, Vivian W Huang, Laura E Targownik, Adam V Weizman, A Hillary Steinhart, Zane Gallinger, Sun-Ho Lee, Greg Rosenfeld, Mark S Silv Journal of the Canadian Association of Gastroenterology.2026;[Epub] CrossRef 2,618 View 395 Download 2 Crossref Real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease: a single-center retrospective study Ji Eun Kim, Yeong Chan Lee, Minjee Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim, Sung Noh Hong Received September 22, 2025 Accepted December 7, 2025 Published online February 10, 2026 DOI: [Epub ahead of print] Abstract PDFSupplementary MaterialPubReaderePub Background/Aims Upadacitinib, a selective Janus kinase 1 inhibitor, has demonstrated efficacy in clinical trials for inflammatory bowel disease (IBD)
